We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
- Authors
Williams, C S; Sheng, H; Brockman, J A; Armandla, R; Shao, J; Washington, M K; Elkahloun, A G; DuBois, R N
- Abstract
Selective COX-2 inhibitors reduce adenoma formation and cancer progression in rodent models of colorectal cancer. To assess the therapeutic activity of selective COX-2 inhibitors, we tested the effect of SC-58125 treatment on the growth of human colon carcinoma cells in nude mice. Delaying treatment by 2, 4, or 7 weeks following implantation of the carcinoma cells resulted in a significant inhibition of tumor growth. Furthermore, short-term (48 hours) treatment with SC-58125 was sufficient to attenuate tumor growth for up to 15 days. SC-58125 treatment did not alter the rate at which cells underwent apoptosis, but did result in a delayed progression through the cell cycle at the G(2)/M transition. Accordingly, p34(cdc2) protein levels and activity were decreased following SC-58125 treatment. We conclude that SC-58125 primarily exerts a cytostatic effect in vivo, which is likely to be mediated through inhibition of progression through the G(2)/M phase of the cell cycle.
- Publication
Neoplasia (New York, N.Y.), 2001, Vol 3, Issue 5, p428
- ISSN
1522-8002
- Publication type
Journal Article
- DOI
10.1038/sj.neo.7900177